QuantiFERON–CMV is not available in the United States.
QuantiFERON–CMV is CE marked for commercial use in Europe

Search Results: Displaying all items (7)

First Author Title Journal Publication Date
Yong MK. Identifying Cytomegalovirus (CMV) complications using the Quantiferon-CMV assay after Allogeneic Hematopoietic Stem Cell Transplantation. The Journal of infectious diseases 2017
Lee SM. Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Annals of laboratory medicine 2017
Herling M. Persistent CMV infection after allogeneic hematopoietic stem cell transplantation in a CMV-seronegative donor-to-positive recipient constellation: Development of multidrug resistance in the absence of anti-viral cellular immunity. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2016
Clari MÁ. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clinical and vaccine immunology : CVI 2012
Gayoso I. Clinical factors influencing phenotype of HCMV-specific CD8+ T cells and HCMV-induced interferon-gamma production after allogeneic stem cells transplantation. Clinical & developmental immunology 2013
Giulieri S. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert review of molecular diagnostics 2011
Fleming T. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. Journal of medical virology 2010